Ülke: Ermenistan
Dil: İngilizce
Kaynak: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
trazodone
Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A.
N06AX05
trazodone
75mg
tablets prolonged-release
(30/2x15/) in blister
Prescription
Registered
2019-12-30
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trittico 75 mg prolonged-release tablets Trittico 150 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Trittico 75 mg prolonged-release tablets _ _ Each tablet contains_: _ _ _75 mg trazodone hydrochloride corresponding to 68,3 mg trazodone _ _ _ _ _ _ Trittico 150 mg prolonged-release tablets Each tablet contains: _ _ 150 mg trazodone hydrochloride corresponding to 136,6 mg trazodone Excipient(s) with known effect: Saccharose For the full list of excipients, see section 6.1._ _ 3. PHARMACEUTICAL FORM Prolonged-release tablets Tablets of color from white to yellowish-white, biconvex, lozenge-shaped, with double breack line on both sides. The tablet can be divided into three equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS: Depressive disorders with or without anxiety 4.2 POSOLOGY AND METHOD OF ADMINISTRATION: The use of the drug is restricted to adult patients. The scored tablets can be divided into three parts in order to permit a gradual dose increase depending on the severity of the disease, weight, age and general condition of the patient. Therapy should begin with an evening administration and with increasing daily doses. Trittico prolonged-released tablets could be administered on an empty stomach or after a meal (see section 5.2). The drug should be administered for therapeutic cycles of at least one month. Adults 75-150 mg/day to be administered in a single dose in the evening before bedtime. The dose can be increased up to 300 mg/day divided in two administrations. In hospitalized patients the dose can be further increased up to 600 mg/day in repeated doses. Elderly: For very elderly, or frail patients, the recommended initial dose is reduced to 100 mg a day, administered in divided doses or as a single night time dose (See Section 4.4). This may be incrementally increased, as described under Adults, under supervision, according to tolerance and efficacy. In general, single doses above 100 Belgenin tamamını okuyun